AbbVie Signs Exclusive Licensing Agreement with Haisco for Pain Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ABBV?
Source: seekingalpha
- Exclusive Licensing Agreement: AbbVie has signed an exclusive licensing agreement with China-based Haisco Pharmaceutical Group to advance the global development of novel pain therapies, indicating AbbVie's strategic positioning in the pain management sector.
- Market Coverage: The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize pain treatment candidates worldwide, excluding mainland China, Hong Kong, and Macau, highlighting AbbVie's focus on international markets.
- Financial Terms: Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in total development, regulatory, and commercial milestone payments, along with tiered royalties on future net sales, providing Haisco with substantial revenue potential.
- Development Stages: The compounds covered by the agreement are currently in development in China across stages ranging from preclinical to Phase 1, demonstrating AbbVie's ongoing commitment to innovative drug development and foresight into future market demands.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 212.400
Low
223.00
Averages
252.00
High
289.00
Current: 212.400
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IMGN853-0420 Trial Shows Efficacy of New Treatment
- Clinical Trial Results: The IMGN853-0420 trial demonstrated a 62.7% objective response rate (ORR) in patients with ≥50% folate receptor alpha (FRα) expression, indicating significant efficacy of mirvetuximab soravtansine-gynx combined with carboplatin, potentially offering a new treatment option for ovarian cancer patients.
- Patient Population Analysis: This multicenter, open-label study enrolled 125 patients, all of whom had received one prior platinum-based chemotherapy, with results showing that 81% of patients did not experience disease progression post-treatment, highlighting the sustained effectiveness of this regimen.
- Safety Assessment: The safety profile of mirvetuximab soravtansine-gynx was consistent with previous studies, with common adverse events being low-grade ocular reactions, over 90% of which were reversible, indicating good tolerability of the treatment.
- Future Research Directions: Investigators emphasized that the combination of mirvetuximab soravtansine-gynx with standard chemotherapy provides a novel treatment strategy for FRα-expressing recurrent platinum-sensitive ovarian cancer, with plans for further exploration of its application potential in other patient populations.
See More
AbbVie Signs Exclusive Licensing Agreement with Haisco for Pain Therapies
- Exclusive Licensing Agreement: AbbVie has signed an exclusive licensing agreement with China-based Haisco Pharmaceutical Group to advance the global development of novel pain therapies, indicating AbbVie's strategic positioning in the pain management sector.
- Market Coverage: The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize pain treatment candidates worldwide, excluding mainland China, Hong Kong, and Macau, highlighting AbbVie's focus on international markets.
- Financial Terms: Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in total development, regulatory, and commercial milestone payments, along with tiered royalties on future net sales, providing Haisco with substantial revenue potential.
- Development Stages: The compounds covered by the agreement are currently in development in China across stages ranging from preclinical to Phase 1, demonstrating AbbVie's ongoing commitment to innovative drug development and foresight into future market demands.
See More
Haisco Enters Exclusive Licensing Agreement with AbbVie
- Exclusive Licensing Agreement: Haisco has entered into an exclusive licensing agreement with global biopharmaceutical company AbbVie, granting rights to develop, manufacture, and commercialize novel pain treatments globally, which is expected to significantly enhance Haisco's international market position.
- Financial Gains: Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in aggregate development, regulatory, and commercial milestone payments, providing robust support for the company's financial stability and future growth.
- Pipeline Expansion: This collaboration will leverage AbbVie's expertise in neuroscience to enhance Haisco's R&D pipeline, advancing multiple compounds aimed at pain-related indications, thereby solidifying its leadership in innovative pharmaceuticals.
- Global Strategy Advancement: Haisco's CEO stated that this partnership aligns closely with the company's international development strategy, aiming to accelerate the global development of innovative pain therapies and enhance the company's competitiveness and influence in the global market.
See More
Haisco Pharmaceutical Enters Exclusive Licensing Agreement with AbbVie
- Exclusive Licensing Agreement: Haisco has entered into an exclusive licensing agreement with global biopharmaceutical company AbbVie, granting rights to develop, manufacture, and commercialize novel pain treatments globally, which is expected to significantly enhance Haisco's international market position.
- Financial Gains: Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in aggregate development, regulatory, and commercial milestone payments, providing strong support for the company's financial stability and future growth.
- Pipeline Expansion: This collaboration leverages AbbVie's expertise in neuroscience to enhance Haisco's R&D pipeline, particularly in key therapeutic areas like pain management, advancing over 50 R&D programs.
- Global Strategy Advancement: Since initiating its global strategy in 2015, Haisco has actively expanded into international markets through various means, and this partnership will further solidify its competitive edge in the global innovative pharmaceuticals market, driving long-term sustainable growth.
See More
AbbVie Presents Late-Breaking Results from IMGN853-0420 Trial at SGO Annual Meeting
- Clinical Trial Progress: AbbVie showcased late-breaking results from the IMGN853-0420 trial at the 2026 Society of Gynecologic Oncology Annual Meeting, evaluating the efficacy of mirvetuximab soravtansine-gynx combined with carboplatin in 125 patients previously treated with platinum-based chemotherapy, indicating strong therapeutic responses that may offer new treatment options for recurrent ovarian cancer patients.
- Efficacy Assessment: The primary endpoint was the objective response rate (ORR) in FRα-positive patients, with results showing favorable responses in the ≥50% FRα subgroup after six cycles of combination therapy, suggesting the potential of this regimen to improve survival rates, particularly for patients with diminished responses to standard platinum-based chemotherapy.
- Innovative Treatment Regimen: The combination of mirvetuximab soravtansine-gynx and carboplatin not only demonstrated robust responses during the treatment phase, but many patients continued to respond during the monotherapy phase, providing new insights for future treatment strategies, especially in patients previously treated with PARP inhibitors.
- Future Research Directions: Investigators emphasized that integrating antibody-drug conjugates with standard chemotherapy could offer more options for FRα-expressing recurrent ovarian cancer patients, and AbbVie plans to further explore this area to meet the urgent need for new therapies among patients.
See More
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
IMGN853-0420 Trial Shows Efficacy of New Treatment
- Clinical Trial Results: The IMGN853-0420 trial demonstrated a 62.7% objective response rate (ORR) in patients with ≥50% folate receptor alpha (FRα) expression, indicating significant efficacy of mirvetuximab soravtansine-gynx combined with carboplatin, potentially offering a new treatment option for ovarian cancer patients.
- Patient Population Analysis: This multicenter, open-label study enrolled 125 patients, all of whom had received one prior platinum-based chemotherapy, with results showing that 81% of patients did not experience disease progression post-treatment, highlighting the sustained effectiveness of this regimen.
- Safety Assessment: The safety profile of mirvetuximab soravtansine-gynx was consistent with previous studies, with common adverse events being low-grade ocular reactions, over 90% of which were reversible, indicating good tolerability of the treatment.
- Future Research Directions: Investigators emphasized that the combination of mirvetuximab soravtansine-gynx with standard chemotherapy provides a novel treatment strategy for FRα-expressing recurrent platinum-sensitive ovarian cancer, with plans for further exploration of its application potential in other patient populations.
See More
AbbVie Signs Exclusive Licensing Agreement with Haisco for Pain Therapies
- Exclusive Licensing Agreement: AbbVie has signed an exclusive licensing agreement with China-based Haisco Pharmaceutical Group to advance the global development of novel pain therapies, indicating AbbVie's strategic positioning in the pain management sector.
- Market Coverage: The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize pain treatment candidates worldwide, excluding mainland China, Hong Kong, and Macau, highlighting AbbVie's focus on international markets.
- Financial Terms: Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in total development, regulatory, and commercial milestone payments, along with tiered royalties on future net sales, providing Haisco with substantial revenue potential.
- Development Stages: The compounds covered by the agreement are currently in development in China across stages ranging from preclinical to Phase 1, demonstrating AbbVie's ongoing commitment to innovative drug development and foresight into future market demands.
See More
Haisco Enters Exclusive Licensing Agreement with AbbVie
- Exclusive Licensing Agreement: Haisco has entered into an exclusive licensing agreement with global biopharmaceutical company AbbVie, granting rights to develop, manufacture, and commercialize novel pain treatments globally, which is expected to significantly enhance Haisco's international market position.
- Financial Gains: Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in aggregate development, regulatory, and commercial milestone payments, providing robust support for the company's financial stability and future growth.
- Pipeline Expansion: This collaboration will leverage AbbVie's expertise in neuroscience to enhance Haisco's R&D pipeline, advancing multiple compounds aimed at pain-related indications, thereby solidifying its leadership in innovative pharmaceuticals.
- Global Strategy Advancement: Haisco's CEO stated that this partnership aligns closely with the company's international development strategy, aiming to accelerate the global development of innovative pain therapies and enhance the company's competitiveness and influence in the global market.
See More
Haisco Pharmaceutical Enters Exclusive Licensing Agreement with AbbVie
- Exclusive Licensing Agreement: Haisco has entered into an exclusive licensing agreement with global biopharmaceutical company AbbVie, granting rights to develop, manufacture, and commercialize novel pain treatments globally, which is expected to significantly enhance Haisco's international market position.
- Financial Gains: Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in aggregate development, regulatory, and commercial milestone payments, providing strong support for the company's financial stability and future growth.
- Pipeline Expansion: This collaboration leverages AbbVie's expertise in neuroscience to enhance Haisco's R&D pipeline, particularly in key therapeutic areas like pain management, advancing over 50 R&D programs.
- Global Strategy Advancement: Since initiating its global strategy in 2015, Haisco has actively expanded into international markets through various means, and this partnership will further solidify its competitive edge in the global innovative pharmaceuticals market, driving long-term sustainable growth.
See More
AbbVie Presents Late-Breaking Results from IMGN853-0420 Trial at SGO Annual Meeting
- Clinical Trial Progress: AbbVie showcased late-breaking results from the IMGN853-0420 trial at the 2026 Society of Gynecologic Oncology Annual Meeting, evaluating the efficacy of mirvetuximab soravtansine-gynx combined with carboplatin in 125 patients previously treated with platinum-based chemotherapy, indicating strong therapeutic responses that may offer new treatment options for recurrent ovarian cancer patients.
- Efficacy Assessment: The primary endpoint was the objective response rate (ORR) in FRα-positive patients, with results showing favorable responses in the ≥50% FRα subgroup after six cycles of combination therapy, suggesting the potential of this regimen to improve survival rates, particularly for patients with diminished responses to standard platinum-based chemotherapy.
- Innovative Treatment Regimen: The combination of mirvetuximab soravtansine-gynx and carboplatin not only demonstrated robust responses during the treatment phase, but many patients continued to respond during the monotherapy phase, providing new insights for future treatment strategies, especially in patients previously treated with PARP inhibitors.
- Future Research Directions: Investigators emphasized that integrating antibody-drug conjugates with standard chemotherapy could offer more options for FRα-expressing recurrent ovarian cancer patients, and AbbVie plans to further explore this area to meet the urgent need for new therapies among patients.
See More
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
